Sofosbuvir

GPTKB entity

Statements (47)
Predicate Object
gptkbp:instanceOf antiviral drug
nucleotide
gptkbp:administeredBy other direct-acting antivirals
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
2013
gptkbp:ATCCode gptkb:J05AX15
gptkbp:bioavailability high
gptkbp:brand gptkb:Sovaldi
gptkbp:CASNumber 1190307-88-0
gptkbp:category antiviral drug
prodrug
nucleotide analog inhibitor
gptkbp:chemicalFormula prodrug of a nucleotide analog
gptkbp:combines gptkb:daclatasvir
ribavirin
ledipasvir
velpatasvir
gptkbp:contraindication severe bradycardia with amiodarone
gptkbp:developedBy gptkb:Gilead_Sciences
gptkbp:discoveredBy gptkb:Michael_Sofia
gptkbp:drugClass direct-acting antiviral
gptkbp:eliminationHalfLife 0.4 hours (sofosbuvir), 27 hours (GS-331007)
gptkbp:excretion urine
gptkbp:genericAvailable yes (in some countries)
gptkbp:hasMolecularFormula C22H29FN3O9P
https://www.w3.org/2000/01/rdf-schema#label Sofosbuvir
gptkbp:indication all HCV genotypes (in combination)
chronic hepatitis C infection
gptkbp:legalStatus prescription only
patented
gptkbp:mechanismOfAction gptkb:NS5B_polymerase_inhibitor
gptkbp:metabolism liver
gptkbp:pregnancyCategory B1 (Australia)
N (US)
gptkbp:priceRange high (notably expensive in US and Europe)
gptkbp:resistantTo rare, but possible with NS5B mutations
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
fatigue
headache
insomnia
gptkbp:target gptkb:HCV_NS5B_polymerase
gptkbp:usedFor treatment of hepatitis C
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:DB09223
gptkbp:bfsLayer 5